Stock Analiz

Verrica Pharmaceuticals Inc. (VRCA) stock forecast and price target

Price $3.56 · data as of November 13, 2026

12-month price target

Average target$13.80
Upside / downside+287.6%
Analysts5
ConsensusStrong buy
Low $9.00Average $13.80High $20.00

Gold marker: average target · white marker: today’s price ($3.56)

Analyst ratings

Strong buy 0Buy 5Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-1.89−52.4%$25M
Next fiscal year
ends December 31, 2027
$-1.36+27.8%$38M
Next quarter
ends December 31, 2026
$-0.51+1.0%$7M
Quarter after
ends March 31, 2027
$-0.44—$7M

Consensus of the analysts covering Verrica Pharmaceuticals, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.

Our model vs. Wall Street

Analysts see 287.6% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Verrica Pharmaceuticals’s intrinsic value about 70% below today’s market value, and it scores 1.2 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Verrica Pharmaceuticals stock price target?

The average 12-month target from 5 analysts is $13.80, 287.6% above the current price of $3.56 Targets range from $9.00 to $20.00.

Is Verrica Pharmaceuticals a buy according to analysts?

The consensus rating is “Strong buy” (5 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is Verrica Pharmaceuticals expected to earn?

Analysts expect EPS of $-1.89 for the fiscal year ending December 31, 2026 and $-1.36 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.